To evaluate the anti-tumor effect of the triple blockade of MEK, PD-L1 and Ido-1, we treated 5 established ex vivo cultures with atezolizumab, selumetinib, or epacadostat or their combination for 6 days. The gene discussed is IDO1; the disease is neoplasm.